Invitation to Roche’s Virtual Oncology/SABCS Investor Event
2025-11-26
 We are pleased to invite investors and analysts to participate in our virtual event on Thursday, 11 December 2025, to highlight new results from Roche’s breast cancer pipeline, including data from the Phase III lidERA breast cancer study evaluating giredestrant as an adjuvant endocrine treatment for people with ER+/HER2- BC that will be presented at the 48th San Antonio Breast Cancer Symposium (SABCS) from 9-12 December 2025. 16:30 - 17:30 CET / 15:30 - 16:30 GMT 10:30 - 11:30 am EST / 07:30 - 08:30 am PST Agenda Introduction Bruno Eschli, Head of Investor Relations Breast cancer franchise update Maura Dickler, VP, Global Head for Breast & Gynecologic Cancers, Product Development Ph III (lidERA) giredestrant in adjuvant ER+/HER2-negative, early BC Aditya Bardia, MD, MPH, FASCO, Professor of Medicine, Geffen School of Medicine, University of California Los Angeles Q&A The slides will be available for download at 15:30 CET on the day of the event. > click here Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via > ir.roche.com *privacy notice Best regards, | |
| Bruno Eschli Head of Investor Relations | Loren Kalm Head of Investor Relations, North America |
| Roche Investor Relations | |
| Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com | |
Investors
Investor updates
stay updated
get the latest news and updates to your inbox.